Daratumumab
Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed in multiple myeloma cells.
Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab. Daratumumab was granted breakthrough therapy drug status in 2013, for multiple myeloma.
It was granted orphan drug status for multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma. It is available in combination with hyaluronidase as daratumumab/hyaluronidase (brand name Darzalex Faspro).
Text derived from https://en.wikipedia.org/w/index.php?oldid=1375335363 under CC BY-SA 4.0; modifications have been made.